A Phase 1 Study Combining MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Irinotecan (Primary) ; MM-151 (Primary) ; Fluorouracil; Folinic acid
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 08 Jan 2017 According to a Merrimack Pharmaceuticals media release, company discontinued this study until conditions are appropriate to invest in this study.
- 08 Jan 2017 Status changed from recruiting to discontinued, as per a Merrimack Pharmaceuticals media release.